Dr. Brandt is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4860 Y St
# Uc
Sacramento, CA 95817Phone+1 916-734-6818Fax+1 916-734-0411
Summary
- James D. Brandt, MD, is Professor of Ophthalmology & Vision Science, Director of the Glaucoma Service and Vice-Chair for International Programs & New Technologies at the University of California, Davis in Sacramento, California.
After receiving a BS degree from Yale University and an MD degree from Harvard Medical School, he pursued a two-year post-doctoral research fellowship in glaucoma-related pharmacology and cell biology at the Schepens Eye Research Institute in Boston before his residency at the USC/LA County/Doheny Eye Institute. He completed a glaucoma fellowship at the Wills Eye Hospital before joining the UC Davis faculty in 1989.
Dr. Brandt’s clinical practice is limited to glaucoma, with a particular focus on infantile and pediatric glaucoma. Dr. Brandt is a frequent volunteer faculty member with ORBIS International, traveling worldwide to train glaucoma specialists in the management of pediatric glaucoma.
Dr. Brandt has served as the Principal Investigator of numerous clinical trials, including the Ocular Hypertension Treatment Study (OHTS). As an OHTS principal investigator, Dr. Brandt initiated the effort to measure central corneal thickness (CCT) as a potential risk factor for glaucoma and has continued to investigate the role of CCT in glaucoma diagnosis and pathogenesis.
Education & Training
- Sidney Kimmel Medical College at Thomas Jefferson University/Wills Eye HospitalFellowship, Glaucoma, 1988 - 1989
- University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Ophthalmology, 1985 - 1988
- Eye Research InstitutePost-Doctoral Fellowship, 1983 - 1985
- University of MinnesotaInternship, Surgery, 1982 - 1983
- Harvard Medical SchoolClass of 1982, M.D.
- Yale UniversityBS, Biology, 1973 - 1978
Certifications & Licensure
- CA State Medical License 1984 - 2026
- MA State Medical License 1983 - 2011
- PA State Medical License 1988 - 2000
- American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2012
- Senior Achievement Award American Academy of Ophthalmology, 2004
- Secretariat Award American Academy of Ophthalmology, 2004
- Join now to see all
Clinical Trials
- Primary Tube Versus Trabeculectomy Study Start of enrollment: 2008 Apr 01
- Baerveldt Plate Area Comparison (BPAC) Start of enrollment: 2010 Jun 01
- Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension Start of enrollment: 2013 Oct 23
Publications & Presentations
PubMed
- 23 citationsIntraocular pressure-induced interlamellar keratitis after LASIK surgery.Richard S. Davidson, James D. Brandt, Mark J. Mannis
Journal of Glaucoma. 2003-02-01 - 53 citationsIontronic microdroplet array for flexible ultrasensitive tactile sensingBaoqing Nie, Ruya Li, James D. Brandt, Tingrui Pan
Lab on a Chip. 2014-02-17 - 15 citationsMicrofluidic tactile sensors for three-dimensional contact force measurementsBaoqing Nie, Ruya Li, James D. Brandt, Tingrui Pan
Lab on a Chip. 2014-10-14
Journal Articles
- Visual field quality control in the Ocular Hypertension Treatment Study (OHTS).Keltner JL, Johnson CA,Cello KE, Bandermann SE, Fan J, Levine RA, Kass MA, Gordon MO and the Ocular Hypertension Treatment Study Group, Journal of Glaucoma 16(8):665-669
- The Ocular Hypertension Treatment Study: Topical Ocular Hypotensive Medication Delays or Prevents Primary Open Angle Glaucoma in African American Individuals.Higginbotham EJ, Gordon MO, Beiser JA, Drake MV, Bennett GR, Wilson MR, Kass MA for the Ocular Hypertension Treatment Study Group, Archives of Ophthalmology 122:813-820
- Baseline risk factors for the development of POAG in the Ocular Hypertension Treatment Study.Coleman AL, Gordon MO, Beiser JA, Kass MA for the Ocular Hypertension Treatment Study Group, American Journal of Ophthalmology 138(4):684-685
- Join now to see all
Books/Book Chapters
Lectures
- 35th Annual UC Davis Health System Eye Center Ophthalmology Symposium - Big Topics on the Big Island: An Update of Comprehensive Ophthalmology 2012UC Davis Health System, Waikoloa, Hawaii - 6/13/2012
- 35th Annual Ophthalmology Symposium: Big Topics on the Big Island; An Update of Comprehensive OphthalmologyUC Davis Health System, Waikoloa, Hawaii - 6/13/2012
- American Glaucoma Society 22nd Annual MeetingAmerican Glaucoma Society (AGS), New York, New York - 3/1/2012
- Join now to see all
Other
- LEO Clinical Update on Glaucoma.Mark B. Sherwood, James D. Brandt, Neil T
San Francisco - LEO Clinical Update on Glaucoma.Mark B. Sherwood, James D. Brandt, Neil T
San Francisco - Measuring Outflow Resistance of an Eye.Pan, Tingrui & Brandt, James D
- Join now to see all
Press Mentions
- UC Davis Health Eye Center 1st to Try Microshunt for Refractory Childhood GlaucomaNovember 17th, 2022
- Silicone Ring May Be Superior to Drops for Glaucoma PatientsMay 5th, 2016
Grant Support
- Ocular Hypertension Treatment Study (OHTS)National Eye Institute1994–2008
Professional Memberships
- Fellow
- American Glaucoma SocietyMember
- Association for Research in Vision and Ophthalmology (ARVO)Member
- Member
- Glaucoma Research SocietyMember
- California Association of Eye Physicians & SurgeonsMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: